A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.

Summary, in English

Despite advances in anti-platelet treatments, there still exists an early increase in both ischemic as well as bleeding events following primary PCI in patients with ST-elevation myocardial infarction (STEMI). Platelet inhibition data of different anti-platelet treatments in the acute phase of a myocardial infarction might offer some insight into these problems. The aim of this study was to evaluate the pharmacodynamic profile of 5 different anti-platelet treatments in the acute phase of STEMI in patients undergoing primary PCI.

• Author: Sasha Koul; Pontus Andell; Andreas Martinsson; Gustav Smith; Fredrik Scherstén; Jan Harnek; Matthias Götberg; Eva Norström; Sven Björnsson; David Erlinge
• Department/s: Cardiology; Division of Hematology and Transfusion Medicine; Clinical Chemistry, Malmö; EXODIAB: Excellence of Diabetes Research in Sweden; EpiHealth: Epidemiology for Health
• Publishing year: 2014
• Language: English
• Publication/Series: BMC Cardiovascular Disorders
• Volume: 14
• Full text: - 2 MB; Download statistics
• Links: http://www.ncbi.nlm.nih.gov/pubmed/25516485?dopt=Abstract; http://dx.doi.org/10.1186/1471-2261-14-189
• Document type: Journal article
• Publisher: BioMed Central (BMC)
• Topic: Cardiac and Cardiovascular Systems
• Status: Published
• Research group: Clinical Chemistry, Malmö
• ISBN/ISSN/Other: ISSN: 1471-2261